MAIA Biotechnology, Inc.
MAIA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MAIA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MAIA
MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies, with its most advanced candidate, ateganosine, currently in clinical trials.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$80.9M
Cash Runway
—
Lead Asset
angiomax rtu (Approved)Next Catalyst
Phase3_Topline · Dec 31, 2027Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 3 clinical trials · 4 catalysts · 10 FDA decisions for MAIA Biotechnology, Inc..
MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies, with its most advanced candidate, ateganosine, currently in clinical trials.
- MAIA Biotechnology is heavily dependent on the success of ateganosine, its most advanced drug candidate, which is still under clinical development [sec · filed 2026-08-21].
- The company has a limited operating history and no history of commercializing pharmaceutical products [sec · filed 2026-08-21].
- As of 2026-06-30, MAIA reported cash & equivalents of $0.0M, net income of -$7.9M, and shareholders' equity of $2.4M [sec].
- There is substantial doubt regarding the company's ability to continue as a going concern, and it will need substantial additional funding [sec · filed 2026-08-21].
- Clinical trials for MAIA's product candidates are expensive, time-consuming, and involve uncertain outcomes [sec · filed 2026-08-21].
What works
- MAIA has a novel technology platform for its product candidates, which may offer differentiation in the oncology space [sec · filed 2026-08-21].
- The company has an upcoming Phase 3 topline readout for THIO sequenced with cemiplimab scheduled for 2027-12-31, indicating progress in late-stage development [catalyst_timeline].
What to weigh
- MAIA has no approved products or commercial revenue, and its ability to generate future revenue depends on successful development and regulatory approval of its candidates [sec · filed 2026-08-21].
- The company faces significant financial risk with zero cash as of 2026-06-30 and a going concern warning, requiring immediate additional funding [sec · filed 2026-08-21].
- Results from preclinical studies or early trials may not be indicative of outcomes in later-stage trials, adding uncertainty to ateganosine's development [sec · filed 2026-08-21].
From the filings
Quoted directly from source documents.
MAIA has substantial doubt about its ability to continue as a going concern and needs additional funding.
“there is substantial doubt regarding our ability to continue as a going concern. We will need substantial additional funding, which may not be available on acceptable terms, or at all.”
SEC filings · August 21, 2026
MAIA is heavily dependent on the success of ateganosine.
“We are heavily dependent on the success of ateganosine, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.”
SEC filings · August 21, 2026
MAIA has a limited operating history and no commercial products.
“We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.”
SEC filings · August 21, 2026
Clinical trials are expensive and uncertain.
“Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes.”
SEC filings · August 21, 2026
Catalyst timeline
- 2027-12-31 · Phase3_Topline — Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs — Topline results from the Phase 3 study of THIO sequenced with cemiplimab are expected, which will be a key value inflection point for the company.
- 2038-04-20 · Patent_Expiry · SINCALIDE — Patent/Exclusivity Expiry: SINCALIDE — Patent exclusivity for SINCALIDE is set to expire, which may affect future revenue if the product is commercialized.
- 2039-05-20 · Patent_Expiry · ANGIOMAX RTU — Patent/Exclusivity Expiry: ANGIOMAX RTU — Patent exclusivity for ANGIOMAX RTU is set to expire, potentially impacting long-term market protection.
- 2042-09-23 · Patent_Expiry · BORTEZOMIB — Patent/Exclusivity Expiry: BORTEZOMIB — Patent exclusivity for BORTEZOMIB is set to expire, which may affect competitive positioning.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; needs immediate funding [sec · filed 2026-08-21].
- Dependence on ateganosine — Business heavily reliant on success of ateganosine; failure would harm business [sec · filed 2026-08-21].
- No commercial history — Limited operating history and no product commercialization experience [sec · filed 2026-08-21].
- Clinical trial risks — Trials are expensive, time-consuming, and outcomes uncertain; early results may not predict later success [sec · filed 2026-08-21].
What to watch
- Phase 3 topline data for THIO sequenced with cemiplimab expected by 2027-12-31 [catalyst_timeline].
- Ability to secure additional funding to continue operations and clinical development [sec · filed 2026-08-21].
- Regulatory progress for ateganosine, including FDA clearance for clinical trials [sec · filed 2026-08-21].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run MAIA Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MAIA Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.37 · 0% dilution
Lead: Approved
5 candidates
4 upcoming, next in ~488d
3 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$12.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,148,090 | $5.8M |
| alyeska investment group, l.p. | 2,500,000 | $3.5M |
| 683 capital management, llc | 1,066,666 | $1.5M |
| geode capital management, llc | 360,481 | $505K |
| vanguard fiduciary trust co | 199,314 | $279K |
| state street corp | 138,950 | $195K |
| blackrock, inc. | 127,978 | $179K |
| corsair capital management, l.p. | 100,000 | $140K |
| northern trust corp | 52,539 | $74K |
| ubs group ag | 51,917 | $73K |
Showing top 10 of 28 institutional holders of MAIA Biotechnology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 4.1%
- Days to cover
- 1.9
- Shares short
- 2,304,530
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MAIA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MAIA Biotechnology, Inc.?
MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies, with its most advanced candidate, ateganosine, currently in clinical trials.
What is MAIA Biotechnology, Inc.'s lead drug candidate?
MAIA Biotechnology, Inc.'s most advanced tracked candidate is angiomax rtu (Approved).
What is MAIA Biotechnology, Inc.'s next catalyst?
MAIA Biotechnology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs " — expected December 31, 2027.
Who is the CEO of MAIA Biotechnology, Inc.?
Dr. Vlad Vitoc M.B.A., M.D. is the chief executive officer of MAIA Biotechnology, Inc. (MAIA).
Where is MAIA Biotechnology, Inc. headquartered?
MAIA Biotechnology, Inc. (MAIA) is headquartered in Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.